Impaired proliferative potential of bone marrow mesenchymal stromal cells in patients with myelodysplastic syndromes is associated with abnormal WNT signaling pathway

Stem Cells and Development

Volumn 23, Issue 14, 2014, Pages 1568-1581

  Pavlaki, Konstantia ^a   Pontikoglou, Charalampos G ^a   Demetriadou, Anthi ^a   Batsali, Aristea K ^a   Damianaki, Athina ^a   Simantirakis, Emmanouil ^a   Kontakis, Michail ^a   Galanopoulos, Athanasios ^b   Kotsianidis, Ioannis ^c   Kastrinaki, Maria Christina ^a   Papadaki, Helen A ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b G GENNIMATAS GENERAL HOSPITAL   (Greece)

^c DEMOCRITUS UNIVERSITY OF THRACE MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ARTICLE; BONE DEVELOPMENT; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CLINICAL ARTICLE; COCULTURE; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; HEMATOPOIETIC STEM CELL; HUMAN; MALE; MESENCHYMAL STROMA CELL; MIDDLE AGED; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; SENESCENCE; TELOMERE HOMEOSTASIS; UPREGULATION; VERY ELDERLY; WNT SIGNALING PATHWAY; ADIPOGENESIS; BONE MARROW CELL; CELL LINEAGE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY;

ADIPOGENESIS; AGED; AGED, 80 AND OVER; BONE MARROW CELLS; CELL DIFFERENTIATION; CELL LINEAGE; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; OSTEOGENESIS; WNT SIGNALING PATHWAY;

EID: 84904110811     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2013.0283     Document Type: Article

References (42)

1. Cazzola M, MG Della Porta, E Travaglino and L Malcovati. (2011). Classification and prognostic evaluation of myelodysplastic syndromes. Semin Oncol 38:627-634.
2. Nolte F and WK Hofmann. (2008). Myelodysplastic syndromes: molecular pathogenesis and genomic changes. Ann Hematol 87:777-795.
3. Tauro S, MD Hepburn, CM Peddie, DT Bowen and MJ Pippard. (2002). Functional disturbance of marrow stromal microenvironment in the myelodysplastic syndromes. Leukemia 16:785-790.
4. Raaijmakers MH, S Mukherjee, S Guo, S Zhang, T Kobayashi, JA Schoonmaker, BL Ebert, F Al-Shahrour, RP Hasserjian, et al. (2010). Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 464:852-857.
5. Pittenger MF, AM Mackay, SC Beck, RK Jaiswal, R Douglas, JD Mosca, MAMoorman, DW Simonetti, S Craig and DR Marshak. (1999). Multilineage potential of adult human mesenchymal stem cells. Science s284:143-147.
6. Bianco P, M Riminucci, S Gronthos and PG Robey. (2001). Bone marrow stromal stem cells: nature, biology, and potential applications. Stem Cells 19:180-192.
7. Flores-Figueroa E, RM Arana-Trejo, G Gutierrez-Espindola, A Perez-Cabrera and H Mayani. (2005). Mesenchymal stem cells in myelodysplastic syndromes: phenotypic and cytogenetic characterization. Leuk Res 29:215-224.
8. Blau O, CD Baldus, WK Hofmann, G Thiel, F Nolte, T Burmeister, S Turkmen, O Benlasfer, E Schumann, et al. (2011). Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts. Blood 118:5583-5592.
9. Flores-Figueroa E, JJ Montesinos, P Flores-Guzman, G Gutierrez-Espindola, RM Arana-Trejo, S Castillo-Medina, A Perez-Cabrera, E Hernandez-Estevez, L Arriaga and H Mayani. (2008). Functional analysis of myelodysplastic syndromes-derived mesenchymal stem cells. Leuk Res 32: 1407-1416.
10. Soenen-Cornu V, C Tourino, ML Bonnet, M Guillier, S Flamant, R Kotb, A Bernheim, JH Bourhis, C Preudhomme, P Fenaux and AG Turhan. (2005). Mesenchymal cells generated from patients with myelodysplastic syndromes are devoid of chromosomal clonal markers and support short- and long-term hematopoiesis in vitro. Oncogene 24:2441-2448.
11. Klaus M, E Stavroulaki, MC Kastrinaki, P Fragioudaki, K Giannikou, M Psyllaki, C Pontikoglou, D Tsoukatou, C Mamalaki and HA Papadaki. (2010). Reserves, functional, immunoregulatory, and cytogenetic properties of bone marrow mesenchymal stem cells in patients with myelodysplastic syndromes. Stem Cells Dev 19:1043-1054.
12. Kastrinaki MC, P Sidiropoulos, S Roche, J Ringe, S Lehmann, H Kritikos, VM Vlahava, B Delorme, GD Eliopoulos, et al. (2008). Functional, molecular and proteomic characterisation of bone marrow mesenchymal stem cells in rheumatoid arthritis. Ann Rheum Dis 67:741-749.
13. Campisi J and F d'Adda di Fagagna. (2007). Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 8:729-740.
14. Wagner W, S Bork, G Lepperdinger, S Joussen, N Ma, D Strunk and C Koch. (2010). How to track cellular aging of mesenchymal stromal cells? Aging (Albany NY) 2:224-230.
15. Kim JA, YJ Kang, G Park, M Kim, YO Park, H Kim, SH Leem, IS Chu, JS Lee, EH Jho and IH Oh. (2009). Identification of a stroma-mediated Wnt/beta-catenin signal promoting self-renewal of hematopoietic stem cells in the stem cell niche. Stem Cells 27:1318-1329.
16. Etheridge SL, GJ Spencer, DJ Heath and PG Genever. (2004). Expression profiling and functional analysis of wnt signaling mechanisms in mesenchymal stem cells. Stem Cells 22:849-860.
17. Zhang DY, HJ Wang and YZ Tan. (2011). Wnt/betacatenin signaling induces the aging of mesenchymal stem cells through the DNA damage response and the p53/p21 pathway. PLoS One 6:e21397.
18. Shuai X, D Zhou, T Shen, Y Wu, J Zhang, X Wang and QI Li. (2009). Overexpression of the novel oncogene SALL4 and activation of the Wnt/beta-catenin pathway in myelodysplastic syndromes. Cancer Genet Cytogenet 194:119-124.
19. Reins J, M Mossner, M Neumann, U Platzbecker, C Schumann, E Thiel and WK Hofmann. (2010). Transcriptional down-regulation of the Wnt antagonist SFRP1 in haematopoietic cells of patients with different risk types of MDS. Leuk Res 34:1610-1616.
20. Jian H, X Shen, I Liu, M Semenov, X He and XF Wang. (2006). Smad3-dependent nuclear translocation of betacatenin is required for TGF-beta1-induced proliferation of bone marrow-derived adult human mesenchymal stem cells. Genes Dev 20:666-674.
21. Swerdlow SH, E Campo, NL Harris, ES Jaffe, SA Pileri, H Stein, J Thiele and JW Vardiman, eds. (2008). WHO Classification of Tumours of Haemopoietic and Lymphoid Tissues. IARC Press, Lyon.
22. Greenberg P, C Cox, MM LeBeau, P Fenaux, P Morel, G Sanz, M Sanz, T Vallespi, T Hamblin, et al. (1997). International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088.
23. Delorme B and P Charbord. (2007). Culture and characterisation of human bone marrow mesenchymal stem cells. In: Methods in Molecular Medicine: Tissue Engineering. Hauser H, M Fussenegger, eds. Humana Press, Totowa, NJ, pp 67-81.
24. Cristofalo VJ, RG Allen, RJ Pignolo, BG Martin and JC Beck (1998). Relationship between donor age and the replicative lifespan of human cells in culture: A reevaluation. Proc Natl Acad Sci U S A 95:10614-10619.
25. Pavlaki KI, MC Kastrinaki, M Klontzas, M Velegraki, I Mavroudi and HA Papadaki. (2012). Abnormal telomere shortening of peripheral blood mononuclear cells and granulocytes in patients with chronic idiopathic neutropenia. Haematologica 97:743-750.
26. Coutinho LH, MH Gilleece, EA De Wynter, A Will and NG Testa. (1993). Clonal and long-term cultures using human bone marrow. In: Haemopoiesis: A Practical Approach. Testa NG, G Molineux, eds. Oxford University Press, Oxford, United Kingdom, pp 75-106.
27. Papadaki HA, AG Eliopoulos, T Kosteas, C Gemetzi, A Damianaki, H Koutala, J Bux and GD Eliopoulos. (2003). Impaired granulocytopoiesis in patients with chronic idiopathic neutropenia is associated with increased apoptosis of bone marrow myeloid progenitor cells. Blood 101:2591-2600.
28. Ling L, V Nurcombe and SM Cool. (2009). Wnt signaling controls the fate of mesenchymal stem cells. Gene 433:1-7.
29. Delorme B, J Ringe, C Pontikoglou, J Gaillard, A Langonne, L Sensebe, D Noel, C Jorgensen, T Haupl and P Charbord. (2009). Specific lineage-priming of bone marrow mesenchymal stem cells provides the molecular framework for their plasticity. Stem Cells 27:1142-1151.
30. Krause U, S Harris, A Green, U Krause, S Harris, A Green, J Ylostalo, S Zeitouni, N Lee and CA Gregory. (2010). Pharmaceutical modulation of canonical Wnt signaling in multipotent stromal cells for improved osteoinductive therapy. Proc Natl Acad Sci U S A 107:4147-4152.
31. Hoffman MD and DS Benoit. (2013). Agonism of Wntbeta- catenin signalling promotes mesenchymal stem cell (MSC) expansion. J Tissue Eng Regen Med. DOI: 10.1002/ term.1736.
32. Tarafdar A, E Dobbin, P Corrigan, R Freeburn and Wheadon H. (2013). Canonical Wnt signaling promotes early hematopoietic progenitor formation and erythroid specification during embryonic stem cell differentiation. PLoS One 8: e81030.
33. Grassinger J, DN Haylock, MJ Storan, GO Haines, B Williams, GA Whitty, AR Vinson, CL Be, S Li, et al. (2009). Thrombin-cleaved osteopontin regulates hemopoietic stem and progenitor cell functions through interactions with alpha9beta1 and alpha4beta1 integrins. Blood 114:49-59.
34. Carrancio S, B Blanco, C Romo, S Muntion, N Lopez- Holgado, JF Blanco, JG Brinon, JF San Miguel, FM Sanchez- Guijo and MC del Canizo. (2011). Bone marrow mesenchymal stem cells for improving hematopoietic function: An in vitro and in vivo model. Part 2: effect on bone marrow microenvironment. PLoS One 6:e26241.
35. Oldershaw RA, SR Tew, AM Russell, K Meade, R Hawkins, TR McKa, KR Brennan and TE Hardingham. (2008). Notch signaling through Jagged-1 is necessary to initiate chondrogenesis in human bone marrow stromal cells but must be switched off to complete chondrogenesis. Stem Cells 26:666-674.
36. Varga G, J Kiss, J Várkonyi, V Vas, P Farkas, K Pálóczi and F Uher F. (2007). Inappropriate Notch activity and limited mesenchymal stem cell plasticity in the bone marrow of patients with myelodysplastic syndromes. Pathol Oncol Res 13:311-319.
37. Schallmoser K, C Bartmann, E Rohde, S Bork, C Guelly, AC Obenauf, A Reinisch, P Horn, AD Ho, D Strunk and W Wagner. (2010). Replicative senescence-associated gene expression changes in mesenchymal stromal cells are similar under different culture conditions. Haematologica 95:867-874.
38. Fehrer C and G Lepperdinger. (2005). Mesenchymal stem cell aging. Exp Gerontol 40:926-930.
39. Zimmermann S, M Voss, S Kaiser, U Kapp, CF Waller and UM Martens. (2003). Lack of telomerase activity in human mesenchymal stem cells. Leukemia 17:1146-1149.
40. Siegel G, T Kluba, U Hermanutz-Klein, K Bieback, H Northoff and R Schäfer. (2013). Phenotype, donor age and gender affect function of human bone marrow-derived mesenchymal stromal cells BMC Med 11:146.
41. Baksh D and Tuan RS. (2007). Canonical and noncanonical Wnts differentially affect the development potential of primary isolate of human bone marrow mesenchymal stem cells. J Cell Physiol 212:817-826.
42. Liu Z, Tang Y, Qiu T, Cao X and Clemens TL. (2006). A dishevelled-1/Smad1 interaction couples WNT and bone morphogenetic protein signaling pathways in uncommitted bone marrow stromal cells. J Biol Chem 281:17156-17163.